Temozolomide — Dosing in CKD & Dialysis

Temozolomide (Alkylating Agent): renal dosing adjustments, dialyzability (Removed by hemodialysis: mean dialyzer removal rate about 85% (pre- vs post-dialyzer plasma) in one patient (Tanaka 2023, PMID 37646650).), and renal-relevant safety risk for CKD and dialysis patients. Educational reference fo

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.